Spinogenix Announces FDA-Authorized Expanded Access Program for SPG302, the First Synaptic Regenerative Therapy to Treat ALS

Spinogenix Announces FDA-Authorized Expanded Access Program for SPG302, the First Synaptic Regenerative Therapy to Treat ALS

FDA Authorizes Expanded Access Program (EAP) to Help Provide Access to SPG302 for 200 ALS Individuals Ineligible for Clinical Study

New method could give patients faster ALS diagnosis - Radio Sweden

A new way to assess MRI images of the brain could lead to faster diagnosis of neurological diseases, such as ALS.Swedish experts have created new support ...

Neurizon’s NUZ-001 trial reveals heightened survival rate for patients with ALS

NUZ-001 increased survival rates compared to untreated matched controls Treatment significantly reduced risk of death by 78.5pc Patients now in 31st month of continuous treatment   Special Report: The NUZ-001 open label extension has completed its 12-month treatment period, demonstrating both good tolerability and promising indications of extended life expectancy in patients with motor neurone disease/amyotrophic lateral sclerosis. Of the 12 pat…

FDA Authorizes Expanded Access Program for ALS Treatment SPG302

The expanded access program enables the collection of real-world data on the safety and efficacy of SPG302, which may support its clinical development for the treatment of amyotrophic lateral sclerosis.

In nerve cells grown in the lab from ALS patients, the compound helped the cells produce more energy and relieve stress in the cell's protein-processing center, called the endoplasmic reticulum. See more